Christopher Heery - Apr 3, 2023 Form 4 Insider Report for Arcellx, Inc. (ACLX)

Role
Chief Medical Officer
Signature
/s/ Michelle Gilson, as Attorney-in-Fact
Stock symbol
ACLX
Transactions as of
Apr 3, 2023
Transactions value $
-$47,121
Form type
4
Date filed
4/4/2023, 07:35 PM
Previous filing
Feb 9, 2023
Next filing
Apr 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACLX Common Stock Options Exercise $45K +3K +19.24% $15.00 18.6K Apr 3, 2023 Direct
transaction ACLX Common Stock Sale -$79.6K -2.6K -13.98% $30.63 16K Apr 3, 2023 Direct F1, F2
transaction ACLX Common Stock Sale -$12.5K -402 -2.51% $31.17 15.6K Apr 3, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACLX Stock Option (right to buy) Options Exercise $0 -3K -1.2% $0.00 246K Apr 3, 2023 Common Stock 3K $15.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022.
F2 Represents the weighted average share price of an aggregate total of 2,598 shares sold in the price range of $30.09 to $30.91 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 402 shares sold in the price range of $31.09 to $31.18 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022.